Published in Leukemia on October 11, 2007
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia (2009) 1.77
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res (2009) 1.29
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol (2009) 1.25
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res (2008) 1.04
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica (2009) 1.01
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia (2013) 1.00
AKT-ing via microRNA. Cell Cycle (2010) 0.97
Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle (2010) 0.93
CD81 is essential for the re-entry of hematopoietic stem cells to quiescence following stress-induced proliferation via deactivation of the Akt pathway. PLoS Biol (2011) 0.91
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia (2014) 0.91
Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle (2010) 0.91
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep (2009) 0.86
Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin (2012) 0.86
SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol (2013) 0.86
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. Mol Pharmacol (2008) 0.85
AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers. Dig Dis Sci (2013) 0.84
Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol (2009) 0.83
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells. Cancer Biol Ther (2012) 0.82
Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol (2010) 0.81
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs (2013) 0.81
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther (2015) 0.80
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther (2012) 0.80
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors. Invest New Drugs (2011) 0.76
Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med (2017) 0.75
Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem (2016) 0.75
Understanding of leukemic stem cells and their clinical implications. Mol Cancer (2017) 0.75
Cardioprotective microRNAs. Pediatr Cardiol (2011) 0.75
Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci (2000) 8.26
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia (2003) 3.89
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia (2003) 2.89
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol (2007) 2.85
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 2.76
Validation of cardiac output studies from the Mostcare compared to a pulmonary artery catheter in septic patients. Minerva Anestesiol (2014) 2.65
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia (2006) 2.28
Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut (2006) 2.24
Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res (2001) 2.17
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia (2008) 2.07
Spinal cord injury caused by direct damage by local anaesthetic infiltration needle. Br J Anaesth (2001) 2.06
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods (1993) 1.96
Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant (2000) 1.95
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia (2008) 1.79
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol Cell (1999) 1.74
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol (2002) 1.73
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene (2008) 1.73
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol (2000) 1.66
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res (1995) 1.62
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia (2003) 1.56
Low day 3 luteinizing hormone values are predictive of reduced response to ovarian stimulation. Hum Reprod (1998) 1.54
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia (2011) 1.51
Cytotoxicity and cytotoxic molecules in invertebrates. Bioessays (2000) 1.51
Intraductal papillary-mucinous neoplasm of the pancreas. A clinicopathologic entity. Arch Pathol Lab Med (1995) 1.50
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
Study on Ki-67 immunoreactivity as a prognostic indicator in patients with advanced gastric cancer. Jpn J Clin Oncol (1998) 1.48
Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol (2011) 1.47
Blood salvage during caesarean section. Br J Anaesth (1998) 1.47
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia (2011) 1.45
Heterogeneous immunophenotype of granular lymphocyte expansions: differential expression of the CD8 alpha and CD8 beta chains. Blood (1992) 1.45
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Ileo-rectal anastomosis in ulcerative colitis: results of a long-term follow-up study. Ital J Gastroenterol (1995) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology (2001) 1.42
Porotic hyperostosis as a marker of health and nutritional conditions during childhood: studies at the transition between Imperial Rome and the Early Middle Ages. Am J Hum Biol (2001) 1.41
A recently developed bifacial platelet-rich fibrin matrix. Eur Cell Mater (2010) 1.40
Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase. Haematologica (2004) 1.40
Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients: diagnostic and prognostic implications. Br J Haematol (1994) 1.40
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
Leiomyomatosis in pelvic lymph nodes. Histopathology (1992) 1.39
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Ultrastructural phenotype of "intestinal-type" cells in columnar-lined esophagus. Ultrastruct Pathol (2002) 1.38
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol (2001) 1.38
CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia (2001) 1.32
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol (2001) 1.32
Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des (2006) 1.31
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia (2007) 1.30
Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol (2000) 1.29
HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol (1987) 1.28
The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia (2002) 1.28
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia (2008) 1.27
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia (2011) 1.26
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem (2011) 1.22
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem (2007) 1.19
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol (2000) 1.18
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia (2003) 1.18
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia (2012) 1.16